Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04380376
Other study ID # PSRI05-20
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date April 30, 2020
Est. completion date October 30, 2020

Study information

Verified date May 2020
Source Federal State Budgetary Institution, Pulmonology Scientific Research Institute
Contact Kiril A Zykov, Prof
Phone +79257729462
Email kirillaz@inbox.ru
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This single-center, prospective, open-label, comparator study, blind for central accessor evaluates the efficacy, safety of inhalations of low-doses of melphalan in patients with pneumonia with confirmed or suspected COVID-19. All patients will receive 0,1 mg of melphalan in 7-10 daily inhalations 1 time per day.


Description:

It was previously shown that in ultra-low (more than 100 times lower than conventional therapeutic) doses inhalations of alkylating drug (melphalan) are effective in severe steroid-resistant bronchial asthma, a form of the disease often characterised by neutrophilic type of inflammation. The exacerbation frequency reduced after the treatment, steroid-sparing effect was shown, morphological signs of bronchial epithelial regeneration were revealed and quality of life of asthmatic patients, treated with ultra-low doses of melphalan, improved. In preclinical studies and studies with volunteers, it was found that inhalations of ultra-low doses of melphalan do not have cytotoxic properties, but have local and systemic anti-inflammatory effects and decrease the activation of lymphocytes due to blockade of heavy β-chain of the interleukin (IL)-2 surface receptor. In addition, in ultra-low concentrations, alkylating agents are able to disrupt the cell signalling through the receptor for tumor necrosis factor (TNF), thereby exerting a protective effect from the cytotoxic activity of TNF-α, which leads to the anti-inflammatory response.

Taking into account, that severe cases of COVID are characterised with hyperergic inflammatory response (and in some cases even with the development of "cytokine storm") it can be assumed that the inhalation use of low-doses of melphalan due to its anti-inflammatory properties can be effective treatment for patients with COVID-associated pneumonia.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date October 30, 2020
Est. primary completion date October 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Age =18 years

2. A patient must have confirmed the diagnosis of bi-lateral moderate / severe pneumonia ( viral or viral-bacterial with confirmed of suspected COVID-19).

3. Presence new infiltrates or increase already available infiltrates of pulmonary infiltrates on lung CT within 48 hours before baseline.

4. A patient has as minimum one of the following symptoms:

fever >38 degrees Celsius, cough, dyspnea, SaO2 (arterial oxygen saturation) <95% (with room air)

Exclusion Criteria:

1. Informed consent is withdrawn by the patient.

2. The patient doesn't follow the instructions of the research staff regarding the requirements of the research protocol.

3. Unable to contact the patient.

4. The researcher believes that participation in the study is not in the interests of the patient and / or further participation in the study is unsafe for the patient's health.

5. There is a violation of the criteria for inclusion and / or non-inclusion in the study.

6. The patient has developed an adverse event, which, according to the researcher, makes further participation in the study unsafe for the patient.

7. The licensing authority or ethics committee, for any reason, decides to discontinue the entire study or close this research center.

8. A female patient becomes pregnant, is planning a pregnancy, or is breastfeeding while participating in this study.

Study Design


Intervention

Drug:
Melphalan
Inhalations with low doses of Melphalan for 7-10 consequent days
Other:
Standard of care
the patients will receive only SOC (standard of care) treatment

Locations

Country Name City State
Russian Federation Clinical hospital Moscow
Russian Federation Kirill Zykov Moscow

Sponsors (3)

Lead Sponsor Collaborator
Federal State Budgetary Institution, Pulmonology Scientific Research Institute Medsi Clinic #1, Moscow, Moscow State University of Medicine and Dentistry

Country where clinical trial is conducted

Russian Federation, 

References & Publications (3)

Pukhal'skii AL, Shmarina GV, Zykov KA, Aleshkin VA. [Effect of steroid therapy on the clinical course of bronchial asthma]. Vestn Ross Akad Med Nauk. 2009;(6):3-9. Review. Russian. — View Citation

Pukhalsky A, Shmarina G, Alioshkin V, Sabelnikov A. Alkylating drugs applied in non-cytotoxic doses as a novel compounds targeting inflammatory signal pathway. Biochem Pharmacol. 2006 Nov 30;72(11):1432-8. Epub 2006 Mar 14. Review. — View Citation

Pukhalsky AL, Shmarina GV. Stimulatory and protective effects of alkylating agents applied in ultra-low concentrations. Pharmacology. 2001;62(3):129-32. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The changes of COVID Ordinal Outcomes Scale The number of patients with the clinical improvement is defined as an improvement of two points (from the status at baseline) on an ordinal scale of clinical improvement on day 28 or discharge from hospital ( whatever occurs earlier)
Death
Hospitalized with Invasive mechanical ventilation plus additional organ support - ECMO / pressors / RRT
Hospitalized with intubation and mechanical ventilation
Hospitalized on non-invasive ventilation or high flow oxygen.
Hospitalized on a mask or nasal prongs.
Hospitalized no oxygen therapy.
Ambulatory, with limitation of activities.
Ambulatory, no limitation of activities. I. No clinical or virological evidence of infection.
baseline vs Day 14, day 28
Primary Percentage of the patients with Clinical Recovery Percentage of the patients with clinical recovery which is defined as a normalisation of fever, respiratory rate, and oxygen saturation, and improvement of cough, sustained for at least 72 hours, or live hospital discharge, whichever comes first.
Normalization and improvement criteria:
Fever - <37°C,
Respiratory rate - =24/minute on room air,
Oxygen saturation - >94% on room air,
Cough - mild or absent on a patient reported scale of severe, moderate, mild, absent.
baseline vs day 7, day 14, day 28
Primary The changes of the Borg's scale The evaluation of changes in modified Borg dyspnea scale. From 0 to 10 units.A lower score means a better clinical result (0 is the absence of dyspnea, and 10 - is maximal dyspnea). Minimal clinically important difference is 1 unit. Baseline vs day 7, day 14, day 28
Secondary CRP level Change in C-reactive protein (CRP) level from baseline in mg/ml. A lower level of CRP means a better clinical result. baseline, day 7, Day 14, Day 28
Secondary Lymphocyte count Change in blood absolute lymphocyte count from baseline. A higher number of lymphocytes means a better clinical result. baseline, day 7, Day 14, Day 28
Secondary D-dimer Change in blood D-dimer level from baseline. A lower level of D-dimer means a better clinical result. baseline, day 7, Day 14, Day 28
Secondary IL-6 Change in peripheral blood IL-6 level from baseline. A lower level of IL-6 means a better clinical result. baseline, day 7, Day 14, Day 28
Secondary Percentage of patients without artificial lung ventilation Percentage of patients without artificial lung ventilation during the study. A lower percentage of patients means a better clinical result. baseline, day 7, Day 14, Day 28
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure